Qpex Biopharma Initiates Phase 1 Study of QPX9003 Targeting Antibiotic-Resistant Pathogens

  19 June 2021

 Qpex Biopharma, Inc., (Qpex) a resistance-focused clinical-stage biopharmaceutical company discovering and developing innovative anti-infective therapies, announced initiation of a Phase 1 study of QPX9003, a next generation intravenous (IV)-administered synthetic polymyxin for infections caused by drug-resistant gram-negative pathogens.

“Infections due to multidrug-resistant (MDR) Acinetobacter sp. and Pseudomonas aeruginosa have resulted in an increased reliance on polymyxin antibiotics originally discovered over 60 years ago,” stated Jason Pogue, PharmD, clinical professor at University of Michigan. “Our research shows that nephrotoxicity occurs in roughly 40% of patients treated with currently available polymyxins, and thus there is a significant unmet need for less toxic therapies.”

The Centers for Disease Control and Prevention (CDC) has listed MDR Acinetobacter and Pseudomonas aeruginosa as serious antimicrobial resistance (AMR) threats, and the World Health Organization considers the development of new drugs to treat these pathogens to be a critical priority.

Further reading: Qpex Biopharma
Author(s): Qpex Biopharma
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

Evotec

JSS University

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





Global Ambassador Network

Welcome at the AMR Insights Ambassador Network!

The AMR Insights Ambassador Network is a growing, distinctive group of professionals who stand out for their commitment, willingness to cooperate and open attitude to combat Antimicrobial resistance (AMR).

More information and free-of-charge registration
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!